Heidelberg Pharma AG

  • WKN: A11QVV
  • ISIN: DE000A11QVV0
  • Land: Deutschland

Nachricht vom 24.06.2021 | 11:12

Heidelberg Pharma AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Heidelberg Pharma AG
24.06.2021 / 11:12
Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Notification of Major Holdings

1. Details of issuer
Name: Heidelberg Pharma AG
Street: Gregor-Mendel-Str. 22
Postal code: 68526
City: Ladenburg
Germany
Legal Entity Identifier (LEI): 391200E09XYBYITR1W32

2. Reason for notification
X Acquisition/disposal of shares with voting rights
  Acquisition/disposal of instruments
  Change of breakdown of voting rights
  Other reason:

3. Details of person subject to the notification obligation
Natural person (first name, surname): Dietmar Hopp
Date of birth: 26 Apr 1940

4. Names of shareholder(s)
holding directly 3% or more voting rights, if different from 3.
dievini Hopp BioTech holding GmbH & Co. KG
DH-LT-Investments GmbH

5. Date on which threshold was crossed or reached:
22 Jun 2021

6. Total positions
  % of voting rights attached to shares
(total of 7.a.)
% of voting rights through instruments
(total of 7.b.1 + 7.b.2)
Total of both in %
(7.a. + 7.b.)
Total number of voting rights pursuant to Sec. 41 WpHG
New 75.32 % 0.00 % 75.32 % 34173009
Previous notification 69.63 % 0.00 % 69.63 % /

7. Details on total positions
a. Voting rights attached to shares (Sec. 33, 34 WpHG)
ISIN Absolute In %
  Direct
(Sec. 33 WpHG)
Indirect
(Sec. 34 WpHG)
Direct
(Sec. 33 WpHG)
Indirect
(Sec. 34 WpHG)
DE000A11QVV0 171538 25567251 0.50 % 74.82 %
Total 25738789 75.32 %

b.1. Instruments according to Sec. 38 (1) no. 1 WpHG
Type of instrument Expiration or maturity date Exercise or conversion period Voting rights absolute Voting rights in %
0 0.00 %
    Total 0 0.00 %

b.2. Instruments according to Sec. 38 (1) no. 2 WpHG
Type of instrument Expiration or maturity date Exercise or conversion period Cash or physical settlement Voting rights absolute Voting rights in %
0 0.00 %
      Total 0 0.00 %

8. Information in relation to the person subject to the notification obligation
  Person subject to the notification obligation is not controlled nor does it control any other undertaking(s) that directly or indirectly hold(s) an interest in the (underlying) issuer (1.).
X Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity:

Name % of voting rights (if at least 3% or more) % of voting rights through instruments (if at least 5% or more) Total of both (if at least 5% or more)
-Herr Dietmar Hopp % % %
-DH-Holding GmbH & Co. KG % % %
-DH-Holding Verwaltungs GmbH % % %
- % % %
-Herr Dietmar Hopp % % %
-Hopp LT Vermögensverwaltungs GmbH % % %
-DH-Capital GmbH & Co. KG % % %
-dievini Hopp BioTech holding GmbH & Co. KG 66.39 % % 66.39 %
- % % %
-Herr Dietmar Hopp % % %
-DH Verwaltungs GmbH % % %
-DH-Capital GmbH & Co. KG % % %
-dievini Hopp BioTech holding GmbH & Co. KG 66.39 % % 66.39 %
- % % %
-Herr Dietmar Hopp % % %
-DH-LT-Investments GmbH 5.69 % % 5.69 %

9. In case of proxy voting according to Sec. 34 para. 3 WpHG
(only in case of attribution of voting rights in accordance with Sec. 34 para. 1 sent. 1 No. 6 WpHG)

Date of general meeting:
Holding total positions after general meeting (6.) after annual general meeting:
Proportion of voting rights Proportion of instruments Total of both
% % %

10. Other explanatory remarks:
 

Date
23 Jun 2021



24.06.2021 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Linde Included in Dow Jones Sustainability World Index for 19th Consecutive Year

02. Dezember 2021, 12:00

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

M1 Kliniken AG

Original-Research: M1 Kliniken AG (von First Berlin Equity Research GmbH): Buy

02. Dezember 2021